Cyteir Therapeutics, Inc. (CYT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYT Stock Price Chart Interactive Chart >
CYT Price/Volume Stats
| Current price | $1.71 | 52-week high | $7.31 |
| Prev. close | $1.59 | 52-week low | $1.13 |
| Day low | $1.56 | Volume | 49,400 |
| Day high | $1.71 | Avg. volume | 209,761 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $2.14 | Market Cap | 60.42M |
Cyteir Therapeutics, Inc. (CYT) Company Bio
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Latest CYT News From Around the Web
Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsLEXINGTON, Mass., November 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights. |
Great news for Cyteir Therapeutics, Inc. (NASDAQ:CYT): Insiders acquired stock in large numbers last yearWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR SymposiumLEXINGTON, Mass., October 12, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targ |
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceLEXINGTON, Mass., August 31, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. |
We're Keeping An Eye On Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
CYT Price Returns
| 1-mo | 16.33% |
| 3-mo | -7.07% |
| 6-mo | -41.24% |
| 1-year | -69.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 3.64% |
| 2022 | -85.49% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...